General Terms and Conditions (GTC) and Privacy Policy

1. drug-explorer.com provides database based scientific information for doctors and is not a tool for self-diagnosis or self-treatment of medical non-experts. drug-explorer.com cannot assume any liability for possible unintended side-effects, damage or other disadvantages that could be attributed to recommendations of drugexplorer.com. drugexplorer.com is not a substitute for consultation of a specialist. As indicated at the end of any results table, any medical decision hast to be taken by a qualified and experienced physician, who is responsible for this decision.

Medicine is not an exact science. On the one hand, there is not a sufficiently well-founded and scientifically valid opinion for every question, and on the other hand recommendations and opinions may differ depending on the scientific source. Not all drugs are approved in all countries. Even though a drug is approved, indications, contraindications and recommendations for dosing may differ between countries. Primarily, the given data refer to european and/or american recommendations. Data have been collected to the best of our knowledge.
drug-explorer.com is unable to assume any liability for the correctness or completeness or up-to-dateness of given data. In particular, it can not be excluded that approvals or recommendations or other factors may differ or change depending on countries or continents.

2. General starting dose and General maximum dose refer to normal weighted adults without any restrictions.

3. If different recommendations for dosing in case of impaired renal or liver function are displayed, the right dosage has always to be chosen in consideratin of the general situation. In most cases, this will be the lower dosage.

4. Allergies to medications are not listed in the contraindications section since this refers to any medication and is logical.

5. In regards to drug-administration during pregnancy and/or lactation period the recommendations oft he american food and drug administration (FDA) are listed, as far as available. As a general point, it should be noted that there is no drug with a proven harmlessness for pregnancy and/or lactation period in several large controlled studies. Relative dose and milk-plasma-ratio are not available for all drugs. If selection is performed within these criteria, only those drugs will be returned for which respective values are present.

6. The selection options regarding the side effects, that should not be present, should be used very carefully and, of course, in consideration of the frequency of the side effects. If a side effect occurs very rare and is selected for not being present, this may cause the exclusion of medication that could be useful.

7. Activity data of antiinfectives refer to the current literature. However, regional or individual variations and resistances may deviate from this. The resulting antiinfectives, that are shown after selection of pathogens, are not automatically suitable for monotherapy of the infection, but show a probable susceptibility. Furthermore, account needs to be taken of the fact that besides from susceptibility tissue penetration plays an important role. Any antiinfective is ineffective, when it does no reach the site of infection. In case of doubt or in severe cases the consultation of a specialist for infectious diseases is recommended.

8. Chosen selection options must have a meaningful relationship. Therefore, it makes no sense to chose e.g. "pneumonia" as indication and "intraocular" as mode of administration.

9. In General contraindications and Absolute contraindications all entered contraindications are listed. In Relative contraindiactions only those contraindications are listed that are explicitly classified as relative contraindications. This means, that selection of a relative contraindication does not exclude that this contraindication may be absolute. In contrast to the side effects, there are no unclassified (i.e. neither relative nor absolute) contraindications.
With regard to the contraindications, that are displayed in a drug’s profile, any single contraindication has to be taken into account, even, if there is an overlap. When e.g. there are the contraindications "Children" and "Children below 8 years", children above 8 years have to be considered as contraindication, too, since they belong to the contraindication "Children". The occasional overlap of contraindications is due to the structure of the database.

10. Side effects are classified according to the frequency of occurence. Side effects without given frequency of occurence are listed in General Side effects where all other side effects are listed, too. This means that selection of a side effect in category General side effects may lead to the exclusion of drugs, that cause the selected side effect very rare, however, no exact frequency of occurence was reported.

11. When Cytochrom P450 options are selected only those substrates, inhibitors and inducers are processed that are clinically relevant. E.g. citalopram is a very weak inhibitor of CYP2C9, CYP2E1 and CYP3A4. Due to a lack of clinical relevance these parameters are not taken into account.

12. Data shown in the results table apply to the respective column, only. If there are several columns no cross-linking is possible between the data of one line (e.g. drug dosing in liver cirrhosis, renal failure and children). In most cases the lowest dosage of the provided dosages will be the right one.

13. In general, mild hepatic impairment is to be understood as Child A cirrhosis, moderate hepatic impairment as Child B cirrhosis and severe hepatic impairment as Child C cirrhosis. However, hepatic impairment is not always linked to cirrhosis (e.g. acute liver failure, alcoholic steatohepatitis). It is clear that hepatic impairment has to be taken into account in these cases in regards to drug selection and dosing, too.

14. If there are several ways for administration of a drug, it is possible that a certain contraindication applies for one mode of administration but not for another. For example, liver cirrhosis is a contraindication for oral administration of budesonide, however, not for inhalative administration. Since contraindications in the database are drug-specific and not administration specific, the selection of a contraindication leads to the exclusion of a drug in all modes of administration. For example, selection of liver cirrhosis as "contraindication that should not be present" would lead to the exclusion of e.g. budesonide in all modes of administration.

15. Frequencies of side effects may vary with different dosages. For example, bleeding complications will be more frequent when a drug like enoxaparin is used with a higer dose.

16. If additional comments are shown in the line of a drug in the results table (e.g. when indications were selected), these comments are only usable when only 1 parameter (i.e. e.g. only 1 indication) was selected.

17. If cardiotoxicity is selected as side effect that should not be present, all drugs that may cause QT prolongation will be excluded as well. If QT prolongation is selected as side effect that should not be present, only those drugs will be excluded for which QT prolongation is a potential side effect. However, drugs that may cause cardiotoxicity beyond QT prolongation will not be excluded.

18. If a drug profile is selected, indications, absolute and relative contraindications are shown. However, not shown are possible comments and restrictions. Any user of a drug is responsible for the right and indication-appropriate use of the drug.

19. drug-explorer.com is not perfect since medicine is not perfect. Different data from different sources may vary or even be contradictory. Apart from that, different people may show differing reactions to one and the same drug. Despite all this limitations, drug-explorer.com is superior to any doctor with regard to multi-criteria drug selection.



Privacy Policy

drug-explorer respects the privacy of users. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our mobile application. Please read this Privacy Policy carefully. IF YOU DO NOT AGREE WITH THE TERMS OF THIS PRIVACY POLICY, PLEASE DO NOT USE THE APPLICATION.

We reserve the right to make changes to this Privacy Policy at any time and for any reason. We will alert you about any changes by updating the "Last updated" date of this Privacy Policy. You are encouraged to periodically review this Privacy Policy to stay informed of updates. You will be deemed to have been made aware of, will be subject to, and will be deemed to have accepted the changes in any revised Privacy Policy by your continued use of the Application after the date such revised Privacy Policy is posted.

This Privacy Policy does not apply to the third-party online/mobile store from which you install the Application.

COLLECTION OF YOUR INFORMATION

The information we may collect via the Application depends on the content and materials you use, and includes:

Derivative Data Information our servers automatically collect when you access the Application, such as selected criteria from the database.

Geo-Location Information We may request access or permission to and track location-based information from your mobile device, either continuously or while you are using the Application, to provide location-based services. If you wish to change our access or permissions, you may do so in your device's settings.

USE OF YOUR INFORMATION

Having accurate information about you permits us to provide you with a smooth, efficient, and customized experience. Specifically, we may use information collected about you via the Application to:
1. Compile anonymous statistical data and analysis for use internally or with third parties.
2. Deliver targeted advertising, and other information regarding promotions and the Application to you.
3. Increase the efficiency and operation of the Application.
4. Monitor and analyze usage and trends to improve your experience with the Application.

DISCLOSURE OF YOUR INFORMATION

We may share information we have collected about you in certain situations. Your information may be disclosed as follows:

Marketing Communications We may share anonymous information with third parties for marketing purposes, as permitted by law.

Third-Party Advertisers We may use third-party advertising companies to serve ads when you visit the Application in order to provide advertisements about goods and services of interest to you.

Business Partners We may share information with our business partners to offer you certain products and services.

Social Media Contacts If you connect to the Application through a social network, your contacts on the social network will see your name, profile photo, and descriptions of your activity.

Other Third Parties We may share information with third parties for marketing purposes, as permitted by law.

Sale or Bankruptcy If we reorganize or sell all or a portion of our assets, undergo a merger, or are acquired by another entity, we may transfer your information to the successor entity. If we go out of business or enter bankruptcy, your information would be an asset transferred or acquired by a third party. You acknowledge that such transfers may occur and that the transferee may decline honor commitments we made in this Privacy Policy.

We are not responsible for the actions of third parties with whom you share personal or sensitive data, and we have no authority to manage or control third-party solicitations.

TRACKING TECHNOLOGIES

Cookies and Web Beacons We may use cookies, web beacons, tracking pixels, and other tracking technologies on the Application to help customize the Application and improve your experience. When you access the Application, your personal information is not collected through the use of tracking technology. Most browsers are set to accept cookies by default. You can remove or reject cookies, but be aware that such action could affect the availability and functionality of the Application. You may not decline web beacons. However, they can be rendered ineffective by declining all cookies or by modifying your web browser's settings to notify you each time a cookie is tendered, permitting you to accept or decline cookies on an individual basis.

THIRD-PARTY WEBSITES

The Application may contain links to third-party websites and applications of interest, including advertisements and external services, that are not affiliated with us. Once you have used these links to leave the Application, any information you provide to these third parties is not covered by this Privacy Policy, and we cannot guarantee the safety and privacy of your information. Before visiting and providing any information to any third-party websites, you should inform yourself of the privacy policies and practices (if any) of the third party responsible for that website, and should take those steps necessary to, in your discretion, protect the privacy of your information. We are not responsible for the content or privacy and security practices and policies of any third parties, including other sites, services or applications that may be linked to or from the Application.

SECURITY OF YOUR INFORMATION

We use administrative, technical, and physical security measures to help protect your personal information. While we have taken reasonable steps to secure the personal information you provide to us, please be aware that despite our efforts, no security measures are perfect or impenetrable, and no method of data transmission can be guaranteed against any interception or other type of misuse. Any information disclosed online is vulnerable to interception and misuse by unauthorized parties. Therefore, we cannot guarantee complete security if you provide personal information.